Literature DB >> 15827798

Intraoperative subareolar injection of 99mTc-labeled sulfur colloid results in consistent sentinel lymph node identification.

Theresa G Zogakis1, Robert E Wetherille, Robert D Christensen, Kevin J Ose, Joel D Friedman, Marybeth Colbert, Charles A Svendsen, Omer K Sanan, Todd M Tuttle.   

Abstract

BACKGROUND: Preoperative parenchymal or peritumoral (PT) injection of (99m)Tc-labeled sulfur colloid (TcSC) is the standard method for sentinel lymph node (SLN) identification in patients with breast cancer. Limitations of this method include variable identification rates, slow transit times, and painful injections. We hypothesize that TcSC will travel to the SLN within minutes after injection into the subareolar (SA) lymphatics, thus making an intraoperative injection technique feasible.
METHODS: One hundred twenty-two women with invasive breast cancer were enrolled onto this prospective study. Immediately after the induction of general anesthesia, patients were injected with 1 to 2 mCi of filtered TcSC in the SA location. Then, 5 mL of 1% isosulfan blue dye was injected into the PT location. The SLN or SLNs were identified as radioactive, blue, or both and removed for pathologic evaluation.
RESULTS: The mean patient age was 56 years. The mean tumor size was 1.5 cm. In 86.1% of patients, a transcutaneous axillary "hot spot" was identified by handheld gamma probe. The mean time from TcSC injection to axillary incision was 17.6 minutes. At least one SLN was identified in 99.2% of patients. The mean number of SLNs identified per patient was 1.83. The mean count of radioactive SLNs was 2715 cps. In 97.2% of patients, blue SLNs were also radioactive.
CONCLUSIONS: TcSC injected into the SA lymphatics rapidly drains to the SLN. The radioactive SLN is easily and quickly identified after an intraoperative SA TcSC injection. The simplicity of this method eliminates the inherent problems associated with standard PT injection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15827798     DOI: 10.1245/ASO.2005.04.021

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  3 in total

1.  A phase I/II trial of 125I methylene blue for one-stage sentinel lymph node biopsy.

Authors:  Jason David Cundiff; Yi-Zarn Wang; Gregory Espenan; Thomas Maloney; Arthur Camp; Laura Lazarus; Alan Stolier; Randy Brooks; Bruce Torrance; Shawn Stafford; James P O'Leary; Eugene A Woltering
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

2.  Using the intraoperative hand held probe without lymphoscintigraphy or using only dye correlates with higher sensory morbidity following sentinel lymph node biopsy in breast cancer: a review of the literature.

Authors:  Suk Chul Kim; Dong Wook Kim; Renee M Moadel; Chun K Kim; Samprit Chatterjee; Michail K Shafir; Arlene Travis; Josef Machac; Borys R Krynyckyi
Journal:  World J Surg Oncol       Date:  2005-09-29       Impact factor: 2.754

3.  Intraoperative Injection of Technetium-99m Sulfur Colloid for Sentinel Lymph Node Biopsy in Breast Cancer Patients: A Single Institution Experience.

Authors:  Julian Berrocal; Lawrence Saperstein; Baiba Grube; Nina R Horowitz; Anees B Chagpar; Brigid K Killelea; Donald R Lannin
Journal:  Surg Res Pract       Date:  2017-04-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.